Abstract: Slide Presentations |


Wael Batobara, MD, FRCPC*; Wayne Kepron, MD, FRCPC; Zoheir Bshouty, MD, PHD
Author and Funding Information

University of Manitoba, Winnipeg, MB, Canada

Chest. 2006;130(4_MeetingAbstracts):153S. doi:10.1378/chest.130.4_MeetingAbstracts.153S-c
Text Size: A A A
Published online


PURPOSE: Prospectively examine the long term effect of low dose Azithromycin (Az) on progression of established Bronchiolitis Obliterance (BO) in lung transplant patients (LTx).

METHODS: Lung trnaplant patients with evidence of chronic rejection for at least 6 months were treated with a loading dose of Az (1 gram) followed by 250 mg PO three times a week. Chronic rejection was defined as a 20% drop in FEV1 from best post operative FEV1 after exclusion of other etiologies. Five data points were recorded for each patient, six month (M6), 3 months (M3) and time zero (0) prior to treatment initiation and 3 and 6 months post treatment initiation. statistical significance was done using ANOVA for repeated measures with specific comparisons.

RESULTS: Individual as well as mean FEV1 data are shown in Figure 1. Six patients (2 females & 4 males), mean age 57.8 yrs (range 42-65 yrs)were included in the study (4 double lung Tx and 2 single lung Tx; 4 patients had COPD, 1 Cystic fibrosis, 1 IPF).All patients were on steroids, calcineurin inhibitors, and cell cycle inhibitors. The time of Az initiation in relation to transplant was between 1 –10 years. Improvement in FEV1 was noticed in 2 patients (500 ml actual improvement in each ) which was sustained up to 6 months .Both patients were COPD who had an accelerated decline in FEV1 in the preceding 6 months prior to Az. There was no relation to transplant date in term of response. Stabilization was noticed in the remaining 4 patients. There were no reported side effects.

CONCLUSION: In this prospective study Az was effective in halting the progression of BO. The best response was observed in 2 patients with accelerated decline in FEV1. This could be the target group for a future randomized placebo controlled trial to confirm the benefit of this treatment.

CLINICAL IMPLICATIONS: Successful treatment of BO may have a significant impact on lung tramsplant survival as it is the main cause of long term mortality.

DISCLOSURE: Wael Batobara, None.

Wednesday, October 25, 2006

10:30 AM - 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543